ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 181 filers reported holding ENANTA PHARMACEUTICALS INC in Q1 2018. The put-call ratio across all filers is 0.33 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $382,000 | -62.9% | 6,183 | -63.9% | 0.02% | -63.5% |
| Q3 2019 | $1,030,000 | +270.5% | 17,147 | +397.6% | 0.05% | +372.7% |
| Q1 2018 | $278,000 | -41.7% | 3,446 | -77.8% | 0.01% | -50.0% |
| Q1 2017 | $477,000 | +78.0% | 15,500 | +93.8% | 0.02% | +37.5% |
| Q4 2016 | $268,000 | -73.9% | 8,000 | -77.1% | 0.02% | -65.2% |
| Q1 2016 | $1,025,000 | +198.8% | 34,915 | +235.2% | 0.05% | +187.5% |
| Q4 2015 | $343,000 | -87.4% | 10,415 | -88.3% | 0.02% | -83.0% |
| Q1 2015 | $2,728,000 | +192.7% | 89,103 | +385.7% | 0.09% | +168.6% |
| Q4 2014 | $932,000 | – | 18,347 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 564,102 | $42,184,000 | 14.63% |
| Fairmount Funds Management LLC | 387,400 | $28,970,000 | 9.55% |
| Soleus Capital Management, L.P. | 318,275 | $23,801,000 | 2.38% |
| Darwin Global Management, Ltd. | 166,190 | $12,428,000 | 1.90% |
| Paradigm Biocapital Advisors LP | 75,507 | $5,646,000 | 1.61% |
| ARMISTICE CAPITAL, LLC | 1,056,000 | $78,968,000 | 1.29% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 150,000 | $11,217,000 | 1.29% |
| Portland Global Advisors LLC | 75,869 | $5,673,000 | 0.95% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,573,829 | $117,691,000 | 0.59% |
| Yorktown Management & Research Co Inc | 10,400 | $778,000 | 0.52% |